PURPOSE: In rectal cancer patients treated with preoperative chemoradiotherapy (CRT) and curative resection, we evaluated the influence of anemia on tumor response to preoperative CRT. METHODS: Between August 2001 and July 2007, 490 patients underwent preoperative CRT, followed by curative-intent surgery. Tumor responses were evaluated based on tumor regression grade (TRG), T- and N-level downstaging, and volume reduction rates. RESULTS: The level of pretreatment hemoglobin (Hb) was 12.9 +/- 1.7 g/dl (range, 7.2-17.6 g/dl). Tumor response rates were significantly different below and above the Hb level of 9.0 g/dl. Specifically, patients with Hb levels >or=9.0 g/dl achieved better tumor responses than those with Hb levels < 9.0 g/dl (rates of TRG 3 or 4-29.0% vs. 0%, p < 0.001). In addition, there is no differences in tumor response between the nontransfusion and transfusion groups of patients with Hb levels >or=9.0 g/dl (rates of TRG 3 or 4-29.1% vs. 23.1%, p = 0.445). CONCLUSIONS: The serum Hb level could be a one of prognostic factors that influences the pathologic tumor response, and pretreatment anemia (below 9.0 g/dl of Hb) is associated with poor response to preoperative CRT.
PURPOSE: In rectal cancerpatients treated with preoperative chemoradiotherapy (CRT) and curative resection, we evaluated the influence of anemia on tumor response to preoperative CRT. METHODS: Between August 2001 and July 2007, 490 patients underwent preoperative CRT, followed by curative-intent surgery. Tumor responses were evaluated based on tumor regression grade (TRG), T- and N-level downstaging, and volume reduction rates. RESULTS: The level of pretreatment hemoglobin (Hb) was 12.9 +/- 1.7 g/dl (range, 7.2-17.6 g/dl). Tumor response rates were significantly different below and above the Hb level of 9.0 g/dl. Specifically, patients with Hb levels >or=9.0 g/dl achieved better tumor responses than those with Hb levels < 9.0 g/dl (rates of TRG 3 or 4-29.0% vs. 0%, p < 0.001). In addition, there is no differences in tumor response between the nontransfusion and transfusion groups of patients with Hb levels >or=9.0 g/dl (rates of TRG 3 or 4-29.1% vs. 23.1%, p = 0.445). CONCLUSIONS: The serum Hb level could be a one of prognostic factors that influences the pathologic tumor response, and pretreatment anemia (below 9.0 g/dl of Hb) is associated with poor response to preoperative CRT.
Authors: E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde Journal: N Engl J Med Date: 2001-08-30 Impact factor: 91.245
Authors: Ben Box; Ian Lindsey; James M Wheeler; Bryan F Warren; Chris Cunningham; Bruce D George; Neil J Mortensen; Adrian C Jones Journal: Dis Colon Rectum Date: 2005-06 Impact factor: 4.585
Authors: A Becker; P Stadler; R S Lavey; G Hänsgen; T Kuhnt; C Lautenschläger; H J Feldmann; M Molls; J Dunst Journal: Int J Radiat Oncol Biol Phys Date: 2000-01-15 Impact factor: 7.038
Authors: Gunnar Birgegård; Matti S Aapro; Carsten Bokemeyer; Mario Dicato; Peter Drings; Javier Hornedo; Maciej Krzakowski; Heinz Ludwig; Sergio Pecorelli; Hans Schmoll; Maurice Schneider; Dirk Schrijvers; Daniel Shasha; Simon Van Belle Journal: Oncology Date: 2005 Impact factor: 2.935
Authors: Nam Kyu Kim; Seung Hyuk Baik; Jin Sil Seong; Hoguen Kim; Jae Kyung Roh; Kang Young Lee; Seung Kook Sohn; Chang Hwan Cho Journal: Ann Surg Date: 2006-12 Impact factor: 12.969
Authors: Miroslav Hodek; Igor Sirák; Alexander Ferko; Július Örhalmi; Eva Hovorková; Dimitar Hadži Nikolov; Petr Paluska; Jindřich Kopecký; Jiří Petera; Milan Vošmik Journal: Strahlenther Onkol Date: 2016-06-06 Impact factor: 3.621
Authors: Chiara Carlomagno; Elide Matano; Roberto Bianco; Carolina Cimminiello; Antonella Prudente; Clorindo Pagliarulo; Anna Crispo; Lucia Cannella; Alfonso DE Stefano; Francesco Paolo D'Armiento; Sabino DE Placido Journal: Exp Ther Med Date: 2010-07-01 Impact factor: 2.447
Authors: W A A Borstlap; C J Buskens; K M A J Tytgat; J B Tuynman; E C J Consten; R C Tolboom; G Heuff; N van Geloven; B A van Wagensveld; C A C A Wientjes; M F Gerhards; S M M de Castro; J Jansen; A W H van der Ven; E van der Zaag; J M Omloo; H L van Westreenen; D C Winter; R P Kennelly; M G W Dijkgraaf; P J Tanis; W A Bemelman Journal: BMC Surg Date: 2015-06-28 Impact factor: 2.102